Canada Spends Logo

Explorez notre analyse du budget 2026

Grant: Doctoral Research Award: Canada Graduate Scholarships

University of Ottawa

$105,000.00

Targeting triple-negative breast cancer stem cells and simultaneously boosting anti-tumor immunity.

EF 2022-23

Résumé
Triple-negative breast cancer (TNBC) is a highly aggressive form of breast cancer that accounts for 10-15% of breast cancer cases and the majority of breast cancer-related deaths. Despite recent research progresses, chemotherapy remains the main option for TNBC patients. Although chemotherapy is great for killing most of the tumour, it enriches a small subset of tumour cells known as cancer stem cells. These cells are unique from all other cells in the body, because they have the ability to regenerate new tumours and limit the body's ability to recognize and fight them. Cancer stem cells cause disease recurrence among patients following chemotherapy. Previous studies have identified cancer-associated proteins, such as CD73, that work to prevent the body's natural defences from recognizing the cancer. However, the role of CD73 in maintaining cancer stem cells remains unknown. Chemotherapies have also shown to increase the amount and function of CD73, further reducing the body's defences against cancers. In this proposed work, I will use a combination of computer modelling and human TNBC cell lines to identify possible relationships between CD73 and other signalling pathways that promote cancer stem cells, subsequently allowing me to identify potential drugs for TNBC patients. To ensure this new treatment can be used in the clinic, I will obtain tumours extracted from actual patients and implant them into mice to test cancer survival after treatment. TNBC cells will also be implanted into mice that both have or lack working immune systems, in order to compare the ability of the drugs to directly kill the cancer with and without the help of the body's natural defences. The overarching goal of my research is to improve our understanding of how cancer stem cells block our body's natural defences against the tumour, and to develop new treatment approaches that can be used in the clinic to improve patient survival and prevent the disease from recurring.
Programme
Doctoral Research Award: Canada Graduate Scholarships
Bénéficiaire
Emplacement
Ontario, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
CIHR Funding Decisions Database

Tel que publié

Id
476301
Name
Mediratta Karan
Region
Ontario
Country
Canada
Orgtype
Institution Paid; Research Institution
Instname2
Cancer Research
Theme2
Biomedical
Prcname2
Doctoral Research Awards - A
Projecttitle
Targeting triple-negative breast cancer stem cells and simultaneously boosting anti-tumor immunity.
Programtype2
Studentship Programs
Orgnameinp2
University of Ottawa
Cihramount2
$105,000
Cihrequipment2
$0
Programname2
Doctoral Research Award: Canada Graduate Scholarships
Keyworddelim
Breast Cancer; Cancer Immunotherapy; Cancer Stem Cells; Cd73 Adenosine Signalling Pathway; Drug Repurposing; Exosomes For Drug Delivery; Immune Checkpoint Inhibition; In Vivo Tumor Modeling; Patient-Derived Xenograft (Pdx); Wnt, Yap, Pi3k, Akt Signalling Pathways
Abstract
Triple-negative breast cancer (TNBC) is a highly aggressive form of breast cancer that accounts for 10-15% of breast cancer cases and the majority of breast cancer-related deaths. Despite recent research progresses, chemotherapy remains the main option for TNBC patients. Although chemotherapy is great for killing most of the tumour, it enriches a small subset of tumour cells known as cancer stem cells. These cells are unique from all other cells in the body, because they have the ability to regenerate new tumours and limit the body's ability to recognize and fight them. Cancer stem cells cause disease recurrence among patients following chemotherapy. Previous studies have identified cancer-associated proteins, such as CD73, that work to prevent the body's natural defences from recognizing the cancer. However, the role of CD73 in maintaining cancer stem cells remains unknown. Chemotherapies have also shown to increase the amount and function of CD73, further reducing the body's defences against cancers. In this proposed work, I will use a combination of computer modelling and human TNBC cell lines to identify possible relationships between CD73 and other signalling pathways that promote cancer stem cells, subsequently allowing me to identify potential drugs for TNBC patients. To ensure this new treatment can be used in the clinic, I will obtain tumours extracted from actual patients and implant them into mice to test cancer survival after treatment. TNBC cells will also be implanted into mice that both have or lack working immune systems, in order to compare the ability of the drugs to directly kill the cancer with and without the help of the body's natural defences. The overarching goal of my research is to improve our understanding of how cancer stem cells block our body's natural defences against the tumour, and to develop new treatment approaches that can be used in the clinic to improve patient survival and prevent the disease from recurring.
Competitiondate
202211
Approvedterm2
3 yrs 0 mth
Pinamesdelim
Mediratta, Karan
Approvedterm
3 ans 0 mois
Cihrcontribution2
~ $105,000~ $0~